Phase II trial of nonpegylated liposomal doxorubicin and low-dose prednisone in second-line chemotherapy for hormone-refractory prostate cancer: A translational study.

M Montanari,F Fabbri,D Turci,S Carloni,R Mattioli,L Frassineti,D Amadori,G Cruciani,E Rondini,S Luzi Fedeli

doi:10.1200/jco.2010.28.15_suppl.4683

Phase II trial of nonpegylated liposomal doxorubicin and low-dose prednisone in second-line chemotherapy for hormone-refractory prostate cancer: A translational study.

M Montanari, F Fabbri + Show 8 more

https://doi.org/10.1200/jco.2010.28.15_suppl.4683

Copy DOI

Journal: Journal of Clinical Oncology	Publication Date: May 20, 2010
Citations: 1

#Chemotherapy For Hormone-refractory Prostate Cancer #Nonpegylated Liposomal Doxorubicin + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

4683 Background: Nonpegylated liposomal doxorubicin(NPLD) (Myocet) has shown an important in vitro activity in hormone-refractory prostate cancer(HRPC) and also in docetaxel-resistant cells, higher...

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Journal of Clinical Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.